Minocycline
Kathryn Dzintars, Pharm.D., BCPS, Paul A. Pham, Pharm.D.
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
- Pneumonia due to susceptible strains, e.g.,
- Skin and skin structure infections, including those caused by S. aureus(if susceptible, MRSA)
- Uncomplicated urethral, endocervical or rectal infections
- Psittacosis caused by Chlamydia psittaci
- Rocky Mountain spotted fever, typhus and the rickettsial typhus group, Q fever, rickettsialpox and other tick fevers caused by Rickettsiae
- Doxycycline is preferred for RMSF and most acute tick-borne rickettsial diseases because of greater clinical experience and guideline support; however, minocycline is likely equivalent in efficacy.
- Cholera caused by Vibrio cholerae (resistance reported)
- Yaws caused by T. pertenue
- Relapsing fever due to Borrelia recurrentis
- Tularemia due to Francisella tularensis
- Campylobacter fetus infections caused by Campylobacter fetus
- Brucellosis due to Brucella species)
- Bartonellosis due to Bartonella bacilliformis
- Mild-moderate acne vulgaris (age >12, minocycline ER only)
- IV Minocycline is also indicated for the treatment of Enterobacterales infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug:
- Other microorganisms, if susceptible
- Acne vulgaris (adjunctive treatment)
- Oral minocycline products are approved for inflammatory lesions of non-nodular moderate-to-severe acne vulgaris; topical foam is approved down to age ≥9 depending on the product.
- Acne rosacea
- Topical 1.5% foam and Emrosi are FDA-approved for inflammatory lesions of rosacea
NON-FDA APPROVED USES
NON-FDA APPROVED USES
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.